# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of...
Chardan Capital analyst Geulah Livshits maintains Prime Medicine (NASDAQ:PRME) with a Buy and lowers the price target from $...
Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0....